GENE - Genetic Technologies Limited

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.0299 (-3.60%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close0.8300
Bid0.0000 x 3000
Ask1.3000 x 1000
Day's Range0.7800 - 0.8287
52 Week Range0.5100 - 2.0400
Avg. Volume45,383
Market Cap13.007M
Beta (3Y Monthly)4.75
PE Ratio (TTM)N/A
EPS (TTM)-0.3000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Genetic Technologies and The Translational Genomics Research Institute of Phoenix, Arizona Sign Memorandum of Understanding

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a provider of world-leading genetic risk assessment test products, is pleased to announce that it has now established a Memorandum of Understanding (MoU) with The Translational Genomics Research Institute (TGen). TGen is an Arizona-based, non-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results. TGen works to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders.

  • GlobeNewswire7 days ago

    Genetic Technologies Asian Operations Established in Hainan, China

    Highlights Genetic Technologies establishes Asian operations in China.The move into Asia includes the formation of Genetic Technologies HK Limited and Hainan Aocheng Genetic.

  • GlobeNewswire2 months ago

    Genetic Technologies Limited Announces Research Collaboration with Two World-Renowned Medical Centres

    MELBOURNE, Australia, Feb. 01, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company is pleased to announce the.

  • GlobeNewswire4 months ago

    Genetic Technologies Limited Provides End of Year Update on the Test Development Program

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, provides today an update on its R&D program for the year. As announced to the market on 16th March 2018, Genetic Technologies Limited has embarked on a collaborative research program with academic research staff from the Centre for Epidemiology and Biostatistics at The University of Melbourne. Led by Professor John Hopper, the research is designed to broaden the applicability of the BREVAGenplus® breast cancer risk assessment test enabling its use in women with an extended family history of disease and will also increase the range of risk factors analysed.

  • GlobeNewswire4 months ago

    Genetic Technologies Limited Announces New Biomedical Blockchain Joint Venture

    MELBOURNE, Australia, Dec. 20, 2018 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), via its subsidiary Gene Ventures Pty Ltd, is pleased to announce that.

  • ACCESSWIRE9 months ago

    Today’s Research Reports on Stocks to Watch: Genetic Technologies and Innovate Biopharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Genetic Technologies saw big gains on news that its breast cancer and colorectal cancer risk assessment tests are on track. Shares of Innovate were headed in the opposite direction on news that the company has filed a securities registration statement amendment with the SEC to issue up to $175 million of new stock and to sell 14 million shares of existing stock. Innovate Biopharmaceuticals, Inc.

  • Genetic Technologies Stock Up on Genetic Test Update
    Market Realist9 months ago

    Genetic Technologies Stock Up on Genetic Test Update

    Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.

  • Benzinga9 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Coda Octopus Group, Inc. (NASDAQ: CODA ) stock soared ...

  • Investopedia11 months ago

    Why KISS Rocker Gene Simmons Sees Dow 30,000

    Beyond 30,000, that’s where the Dow Jones Industrial Average (DJIA) is headed, according to Gene Simmons, known by many rock n’ roll fans as the KISS Demon. As of the close of trading on Tuesday, the Dow was sitting around 24,360, down 1.5% on the year. Since 1985, the Dow has gone through good times and bad, but has risen overall by nearly 1,800%.